Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B

Journal of Medical Virology

Volumn 81, Issue 7, 2009, Pages 1151-1156

  Iacomi, Fabio ^a   Vincenti, Donatella ^a   Vairo, Francesco ^a   Solmone, Mariacarmela ^a   Mariano, Andrea ^a   Piselli, Pierluca ^a   Puro, Vincenzo ^a   Capobianchi, Maria Rosaria ^a   Antonucci, Giorgio ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

HBV genotype; HBV resistance; HIV HBV Co infection; Lamivudine; Vaccine escape mutants

Indexed keywords

ASPARTIC ACID; GLUTAMIC ACID; ISOLEUCINE; LAMIVUDINE; LEUCINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; VALINE; ANTIVIRUS AGENT; POL PROTEIN; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CHRONIC HEPATITIS; DRUG TREATMENT FAILURE; ENVELOPE GENE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PHENOTYPE; PROTEIN MOTIF; SEQUENCE ANALYSIS; STRUCTURAL GENE; VIRUS MUTATION; ANTIVIRAL RESISTANCE; DNA SEQUENCE; GENETICS; MIDDLE AGED; MISSENSE MUTATION; RETROSPECTIVE STUDY; VIROLOGY;

HEPATITIS B VIRUS;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, ENV; GENE PRODUCTS, POL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

EID: 67650001532     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21505     Document Type: Article

References (23)

1. REFERENCES Akenami FO, Koskiniemi M, Ekanem EE, Bolarin DM, Vaheri A. 1997. Seroprevalence and coprevalence of HIV and HBsAg in Nigerian children with/without protein energy malnutrition. Acta Trop 64:167-174. (Pubitemid 27191480)
2. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677. (Pubitemid 28264693)
3. Alter MJ. 2006. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44:S6-S9. (Pubitemid 43053865)
4. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T. 1999. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30:1302-1306. (Pubitemid 29510871)
5. Breslow NE, Day NE. 1980. Statistical methods in cancer research.Vol. I - The analysis of case-control studies. Lyon, France: IARC Scientific Publication, pp. 192-246.
6. Delaney WE IV, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833-11841. (Pubitemid 37271680)
7. Honkoop P, deManRA, Niesters HG,SchalmSW.1998. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 29:510-511.
8. Jain MK, Opio CK, Osuagwu CC, Pillai R, Keiser P, Lee WM. 2007. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Clin Infect Dis 44: 996-1000.
9. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. 2001. Fatal submassive hepatic necrosis associated with tyrosinemethionine- aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 33:403-405. (Pubitemid 32664850)
10. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572. (Pubitemid 29357527)
11. Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. 2001. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 34:583-589. (Pubitemid 32786651)
12. Locarnini S, Warner N. 2007. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 12:H15-H23.
13. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. 2006. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20:863-870. (Pubitemid 43731568)
14. Pan XP, Li LJ, DuWB, Li MW, Cao HC, Sheng JF. 2007. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C. J Viral Hepat 14:767-774. (Pubitemid 47561581)
15. Pérez-Olmeda M, Núñez M, García-Samaniego J, Ríos P, González- Lahoz J, Soriano V. 2003. Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: Therapeutic implications. AIDS Res Hum Retroviruses 19:657-659.
16. Ramos B,Núñez M, Martín-Carbonero L, Sheldon J, Rios P, Labarga P, Romero M, Barreiro P, García-Samaniego J, Soriano V. 2007. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 44:557-561.
17. Schaefer S. 2005. Hepatitis B virus: Significance of genotypes. J Viral Hepat 12:111-124.
18. Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, Locarnini S, Zoulim F, Soriano V. 2007. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 46:279-282. (Pubitemid 350287353)
19. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC. 2002. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293:305-313. (Pubitemid 34928851)
20. UNAIDS. 2006. AIDS epidemic update: Special report on HIV/AIDS: 2006. Available at: http://www.unaids.org/pub/EpiReport/2006/ 2006-EpiUpdate.en.pdf. Accessed March 23, 2008.
21. Yao JD, Beld MG, Oon LL, Sherlock CH, Germer J, Menting S, Se Thoe SY, Merrick L, Ziermann R, Surtihadi J, Hnatyszyn HJ. 2004. Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 assay. J Clin Microbiol 42:800-806. (Pubitemid 38222665)
22. Zöllner B, Schäfer P, Feucht HH, Schröter M,Petersen J, Laufs R. 2001. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 65:659-663.
23. Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, Schröter M, Laufs R, Feucht HH. 2004. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 39:42-50. (Pubitemid 38461465)